# US 2026/0108497 A1 · Oxazole compound and pharmaceutical composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0108497 A1
- Document ID: US20260108497A1
- Status: Published application
- Kind: A1
- Application number: 19/422,682
- Filed: 2025-12-17
- Published: 2026-04-23
- Earliest claimed: 2005-11-15
- Assignees: Otsuka Pharmaceuticalc., Ltd.
- Applicants: Otsuka Pharmaceutical Co., Ltd.
- Inventors: Minoru OKADA; Masaya Kato; Norifumi Sato; Tetsuyuki Uno; Hideki Kitagaki; Junpei Haruta; Hidetaka Hiyama; Tomonori Shibata
- Web page: https://patentgrep.com/patent/US20260108497A1

## CPC

- A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 263/32: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 263/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C12N 9/16: acting on ester bonds (3.1)
- C12Y 301/04012: Sphingomyelin phosphodiesterase (3.1.4.12)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by —Y1-A1- or —Y2—C(═O)— wherein Y1 is a group such as —C(═O)—, A1 is a group such as a lower alkylene group, and Y2 is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.

## Claims

### Claim 1

A method for obtaining cells expressing phosphodiesterase (PDE) 4, comprising:
preparing a vector containing cDNA encoding human PDE4,
introducing the vector into mammalian cells,
cultivating the cells in a medium, and
collecting the cells

### Claim 2 (depends on 1)

The method of claim 1, wherein the cells are COS-7 cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein the vector is a plasmid vector.

### Claim 4

A method for treating or preventing phosphodiesterase 4-mediated and/or tumor necrosis factor-α-mediated disease, the method comprising administering to human or animal in need thereof an oxazole compound represented by Formula (1)
wherein R1 is an aryl group which may have one or more substituents selected from the following (1-1) to (1-11):
(1-1) hydroxy groups,
(1-2) unsubstituted or halogen-substituted lower alkoxy groups,
(1-3) lower alkenyloxy groups,
(1-4) lower alkynyloxy groups,
(1-5) cyclo C3-8 alkyl lower alkoxy groups,
(1-6) cyclo C3-8 alkyloxy groups,
(1-7) cyclo C3-8 alkenyloxy groups,
(1-8) dihydroindenyloxy groups,
(1-9) hydroxy lower alkoxy groups,
(1-10) oxiranyl lower alkoxy groups, and
(1-11) protected hydroxy groups;
R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents selected from the following (2-1) to (2-10):
(2-1) hydroxy groups,
(2-2) unsubstituted or halogen-substituted lower alkoxy groups,
(2-3) unsubstituted or halogen-substituted lower alkyl groups,
(2-4) lower alkenyloxy groups,
(2-5) halogen atoms,
(2-6) lower alkanoyl groups,
(2-7) lower alkylthio groups,
(2-8) lower alkylsulfonyl groups,
(2-9) oxo groups, and
(2-10) lower alkoxy lower alkoxy groups; and
W is a divalent group represented by Formula (i) or (ii):
wherein A1 is a lower alkenylene group, or a lower alkylene group which may have one or more substituents selected from the group consisting of hydroxy groups and lower alkoxycarbonyl groups,
Y1 is a direct bond, —C(═O)—, —C(═O)—N(R3)—, —N(R4)—C(═O)—, —S(O)m—NH—, or —S(O)n—
wherein R3 and R4 are each independently a hydrogen atom or a lower alkyl group, and m and n are each independently an integer from 0 to 2, and
Y2 is a piperazinediyl group, or a divalent group represented by Formula (iii) or (iv):
wherein A2 and A3 are each independently a lower alkylene group, and R5 and R6 are each independently a hydrogen atom or a lower alkyl group;
or a salt thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the disease is at least one selected from the group consisting of bronchial asthma, chronic obstructive pulmonary disease, dermatoses, psoriasis, toxic and allergic contact eczema, atopic dermatitis, alopecia areata, learning, memory, and/or cognition disorders associated with Alzheimer's or Parkinson's diseases, manic-depressive psychosis, schizophrenia, anxiety disorder, systemic and local arthritic disorders, knee osteoarthritis, articular rheumatism, gastrointestinal diffuse inflammation, Crohn's disease and ulcerative colitis, allergic and/or chronic immune-mediated inflammatory diseases in the upper respiratory tract, allergic rhinitis/sinusitis, chronic rhinitis/sinusitis, and allergic conjunctivitis.

### Claim 6 (depends on 4)

The method of claim 4, wherein R1 is a phenyl group which has 1 to 3 substituents selected from the following (1-2), (1-3), (1-4) and (1-5):
(1-2) unsubstituted or halogen-substituted lower alkoxy groups, (1-3) lower alkenyloxy groups,
(1-4) lower alkynyloxy groups, and
(1-5) cyclo C3-8 alkyl lower alkoxy groups;
R2 is a phenyl group or a pyridyl group each of which may have 1 to 3 substituents selected from the group consisting of the following (2-2), (2-3), (2-4) and (2-5):
(2-2) unsubstituted or halogen-substituted lower alkoxy groups,
(2-3) unsubstituted or halogen-substituted lower alkyl groups,
(2-4) lower alkenyloxy groups, and
(2-5) halogen atoms;
W is a divalent group represented by Formula (i):
wherein A1 is a lower alkylene group, and
Y1 is —C(═O)— or —C(═O)—N(R3)—
wherein R3 is a hydrogen atom.

### Claim 7 (depends on 4)

The method of claim 4, wherein R1 is a phenyl group having two substituents selected from the following (1-2), (1-3), (1-4) and (1-5):
(1-2) unsubstituted or halogen-substituted lower alkoxy groups,
(1-3) lower alkenyloxy groups,
(1-4) lower alkynyloxy groups, and
(1-5) cyclo C3-8 alkyl lower alkoxy groups;
R2 is a phenyl group or a pyridyl group each of which may have 1 to 2 substituents selected from the following (2-2), (2-3), (2-4) and (2-5):
(2-2) unsubstituted or halogen-substituted lower alkoxy groups,
(2-3) unsubstituted or halogen-substituted lower alkyl groups,
(2-4) lower alkenyloxy groups, and
(2-5) halogen atoms; and
W is a divalent group represented by Formula (i):
wherein A1 is a lower alkylene group, and
Y1 is —C(═O)— or —C(═O)—N(R3)—
wherein R3 is a hydrogen atom.

### Claim 8 (depends on 4)

The method of claim 4, wherein R1 is a phenyl group substituted on the phenyl ring with two lower alkoxy groups, a phenyl group substituted on the phenyl ring with one lower alkoxy group and one cyclo C3-8 alkyl lower alkoxy group, a phenyl group substituted on the phenyl ring with one lower alkoxy group and one halogen-substituted lower alkoxy group, a phenyl group substituted on the phenyl group with one lower alkoxy group and one lower alkenyloxy group, a phenyl group substituted on the phenyl ring with one halogen-substituted lower alkoxy group and one cyclo C3-8 alkyl lower alkoxy group, a phenyl group substituted on the phenyl ring with one halogen-substituted lower alkoxy group and one lower alkenyloxy group, or a phenyl group substituted on the phenyl ring with two halogen-substituted lower alkoxy groups;
R2 is a lower alkoxyphenyl group, a lower alkenyloxyphenyl group, a halogen-substituted lower alkoxyphenyl group, a lower alkylpyridyl group, or a phenyl group substituted on the phenyl ring with one lower alkoxy group and one halogen atom; and
W is a divalent group represented by Formula (i):
wherein A1 is a C1-4 alkylene group, and
Y1 is —C(═O)— or —C(═O)—N(R3)—
wherein R3 is a hydrogen atom.

### Claim 9 (depends on 4)

The method of claim 4, wherein R1 is a phenyl group substituted on the phenyl ring with two lower alkoxy groups, a phenyl group substituted on the phenyl ring with one lower alkoxy group and one cyclo C3-8 alkyl lower alkoxy group, a phenyl group substituted on the phenyl ring with one lower alkoxy group and one halogen-substituted lower alkoxy group, a phenyl group substituted on the phenyl group with one lower alkoxy group and one lower alkenyloxy group, a phenyl group substituted on the phenyl ring with one halogen-substituted lower alkoxy group and one cyclo C3-8 alkyl lower alkoxy group, a phenyl group substituted on the phenyl ring with one halogen-substituted lower alkoxy group and one lower alkenyloxy group, or a phenyl group substituted on the phenyl ring with two halogen-substituted lower alkoxy groups;
R2 is a lower alkoxyphenyl group, a lower alkenyloxy phenyl group, a halogen-substituted lower alkoxyphenyl group, a lower alkylpyridyl group, or a phenyl group substituted on the phenyl ring with one lower alkoxy group and one halogen atom; and
W is a divalent group represented by Formula (i):
wherein A1 is a C1-4 alkylene group, and
Y1 is —C(═O)—.

### Claim 10 (depends on 4)

The method of claim 4, wherein R1 is a phenyl group substituted on the phenyl ring with one lower alkoxy group and one halogen-substituted lower alkoxy group, a phenyl group substituted on the phenyl ring with one halogen-substituted lower alkoxy group and one cyclo C3-8 alkyl lower alkoxy group, or a phenyl group substituted on the phenyl ring with one halogen-substituted lower alkoxy group and one lower alkenyloxy group;
R2 is a lower alkoxyphenyl group or a lower alkylpyridyl group; and
W is a divalent group represented by Formula (i):
wherein A1 is a C1-4 alkylene group, and
Y1 is —C(═O)—N(R3)—
wherein R3 is a hydrogen atom.
